Walgreens Boots Alliance adjusts outlook after results, shares under pressure on NYSE

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-25, 14:12.

Walgreens Boots Alliance, Inc. (US9314271019) reported a quarterly net loss and cut its dividend earlier this year as it recalibrates strategy for its U.S. healthcare push, as detailed in its March 2026 earnings release. The NYSE-listed pharmacy chain has since adjusted its full-year outlook and continues to draw cautious commentary from Wall Street analysts.

What the latest earnings showed

In its second-quarter fiscal 2026 report published in late March, Walgreens Boots Alliance disclosed a net loss attributable to the company in the low hundreds of millions of dollars, driven by restructuring charges and softer retail pharmacy trends in the United States. The company reported that total sales rose modestly year on year, supported by its international pharmacy and healthcare services segments. The official quarterly results on the investor relations site detailed these figures and reiterated management's focus on cost savings.

Management used the earnings release and accompanying call to refine its full-year fiscal 2026 outlook, highlighting expectations for adjusted earnings per share within a narrowed range compared with prior guidance. Executives emphasized that restructuring actions and ongoing portfolio optimization should help protect margins in a challenging U.S. retail environment. The New York Stock Exchange listing remains an important reference for global investors assessing the company's progress.

Analysts remain cautious on the shares

Following the earnings update and dividend reduction announced in January 2025, several research houses reiterated cautious views on Walgreens Boots Alliance, often with Hold or Underweight ratings and subdued 12-month price targets. Analysts have pointed to structural headwinds in U.S. retail pharmacy, reimbursement pressure and execution risk in healthcare services as key reasons for their stance. A recent consensus overview on a major analyst-aggregation platform shows that a minority of covering banks still rate the stock Buy, while most recommend Neutral or Sell. Reuters analyst estimates for WBA summarize this split view with modest earnings growth expectations over the next two years.

Some U.S. brokerages, such as large Wall Street investment banks and regional research firms, have highlighted that execution on cost savings and healthcare profitability could lead to upside if management delivers consistently over several quarters. At the same time, these notes often stress that competitive pressure from peers such as CVS Health and big-box retailers makes a rapid turnaround less likely. For international investors tracking the broader S&P 500 healthcare and consumer staples segments, Walgreens Boots Alliance serves as a barometer for traditional brick-and-mortar pharmacy models under digital disruption.

The product behind the stock

Walgreens Boots Alliance generates most of its revenue from its retail pharmacies and health and wellness stores, particularly the Walgreens-branded outlets in the United States. These locations offer prescription medications, over-the-counter drugs, health and beauty products, and basic convenience items. The company also operates the Boots retail chain in the United Kingdom and Ireland, providing similar pharmacy and beauty offerings under the Boots brand.

Where the stock trades today

Walgreens Boots Alliance shares trade on the New York Stock Exchange under the ticker WBA, with the latest available price data pointing to trading in the low tens of U.S. dollars per share as of the most recent market close in New York.

This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.